Omeprazole for gastroesophageal reflux disease in the first 2 years of life: a dose-finding study with dual-channel pH monitoring
- PMID: 17592364
- DOI: 10.1097/MPG.0b013e318049cbcc
Omeprazole for gastroesophageal reflux disease in the first 2 years of life: a dose-finding study with dual-channel pH monitoring
Abstract
Background and aim: Gastroesophageal reflux occurs in the majority of infants, with severity ranging from asymptomatic to severe esophagitis and failure to thrive. Omeprazole is recognized as a safe and effective treatment of gastroesophageal reflux in older children, at an initial dosage of 0.7 mg x kg(-1) x day(-1). To our knowledge, no dose-finding studies have been carried out in children under 2 years of age. The aim of the present study was to prospectively determine the dosage of omeprazole required to treat symptomatic gastroesophageal reflux in children younger than 2 years.
Patients and methods: Children under 2 years with clinical suspicion of gastroesophageal reflux underwent 24-hour dual-channel intraesophageal/gastric pH monitoring. A reflux index above 10% in children under 1 year and above 6% in children older than 1 year was deemed significant. Treatment with omeprazole at an initial dosage of 0.7 mg x kg(-1) x day(-1) (in 2 divided doses) was followed by dual-channel pH study after 14 days. The dosage was increased in increments of 0.7 mg x kg(-1) x day(-1), and pH studies were repeated until the gastroesophageal reflux was controlled.
Results: Ten children (5 male, 5 female), mean age 7.75 months (range, 1.25-20 months), were investigated. The initial median reflux index was 18.5% (range, 6.5%-56.3%). Follow-up median reflux index was improved at 1.6% (0.1%-8.1%) (P < 0.05). The median dosage required was 1.05 mg x kg(-1) x day(-1). Four children required 1.4 mg x kg(-1) x day(-1), and 1 required 2.8 mg x kg(-1) x day(-1). Corrected reflux index improved from 34.8% (16.8%-90.8%) to 20.1% (0.4%-100%) but did not achieve statistical significance. There were no serious complications or side effects.
Conclusions: Omeprazole is an effective treatment for gastroesophageal reflux in children younger than 2 years. The majority respond to a dosage of 0.7 mg x kg(-1) x day(-1), but increased dosages up to 2.8 mg x kg(-1) x day(-1) may be required.
Similar articles
-
Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group.Am J Gastroenterol. 2000 Nov;95(11):3101-6. doi: 10.1111/j.1572-0241.2000.03256.x. Am J Gastroenterol. 2000. PMID: 11095324 Clinical Trial.
-
24-hour esophageal pH monitoring in children with pathological acid gastroesophageal reflux: primary and secondary to food allergy. Part I. Intraesophageal pH values in distal channel; preliminary study and control studies--after 1, 2, 4 and 9 years of clinical observation as well as dietary and pharmacological treatment.Adv Med Sci. 2007;52:199-205. Adv Med Sci. 2007. PMID: 18217419
-
Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy.Am J Gastroenterol. 1996 Aug;91(8):1527-31. Am J Gastroenterol. 1996. PMID: 8759655 Clinical Trial.
-
[Drug therapy of gastroesophageal reflux (a prospective controlled clinical trial)].Orv Hetil. 1998 May 3;139(18):1077-81. Orv Hetil. 1998. PMID: 9608770 Review. Hungarian.
-
Gastroesophageal reflux in infants and children. When to reassure and when to go further.Can Fam Physician. 2001 Oct;47:2045-50, 2053. Can Fam Physician. 2001. PMID: 11723599 Free PMC article. Review.
Cited by
-
Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review.Br J Clin Pharmacol. 2015 Aug;80(2):200-8. doi: 10.1111/bcp.12619. Epub 2015 Jun 11. Br J Clin Pharmacol. 2015. PMID: 25752807 Free PMC article. Review.
-
Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease.Eur J Clin Pharmacol. 2009 Feb;65(2):209-16. doi: 10.1007/s00228-008-0560-0. Epub 2008 Sep 17. Eur J Clin Pharmacol. 2009. PMID: 18797857 Free PMC article.
-
Development and Stability Study of an Omeprazole Suppository for Infants.Eur J Drug Metab Pharmacokinet. 2020 Oct;45(5):627-633. doi: 10.1007/s13318-020-00629-1. Eur J Drug Metab Pharmacokinet. 2020. PMID: 32594306 Free PMC article.
-
Comparative Effectiveness Study of Chloramphenicol and Ceftriaxone in the Treatment of Typhoid Fever in Children Admitted to Putri Hijau Kesdam I/Bb Hospital Medan.Open Access Maced J Med Sci. 2019 Nov 14;7(22):3847-3851. doi: 10.3889/oamjms.2019.517. eCollection 2019 Nov 30. Open Access Maced J Med Sci. 2019. PMID: 32127989 Free PMC article.
-
Delayed-release oral suspension of omeprazole for the treatment of erosive esophagitis and gastroesophageal reflux disease in pediatric patients: a review.Clin Exp Gastroenterol. 2010;3:17-25. doi: 10.2147/ceg.s6620. Epub 2010 Mar 29. Clin Exp Gastroenterol. 2010. PMID: 21694842 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical